Scalper1 News
IBD 50 stock Salix Pharmaceuticals missed expectations with its second-quarter report late Thursday, ending a disappointing day for several large specialty-drug makers. Salix (SLXP) said earnings more than doubled vs. the year-earlier quarter to $1.59 a share, missing analysts’ consensus by 13 cents. Sales rose 62% to $382 million, some $17 million below analysts’ estimates. Full-year guidance was also light. Salix forecast revenue at $1.6 Scalper1 News
Scalper1 News